Evidence map›Paper›PMID 40679752›Full record

ReviewDermatology and therapy2025

Biologic Sequence for the Treatment of Psoriatic Arthritis Following Nonresponse: A Narrative Review.

Nicole D Boswell, Alexa Ries, Kenneth B Gordon, Shikha Singla

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nicole D BoswellDepartment of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Alexa RiesDepartment of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Kenneth B GordonDepartment of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Shikha SinglaDepartment of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, USA. ssingla@mcw.edu.ORCID http://orcid.org/0000-0002-5540-8850

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriatic arthritis (PsA) is a complex, heterogeneous disease affecting multiple domains which necessitates a nuanced approach to treatment. While tumor necrosis factor (TNF) inhibitors have historically been the preferred first line therapy, increasing evidence highlights the efficacy of interleukin (IL) 17 and IL-23 inhibitors, particularly in cases of nonresponse to TNF inhibitors. These targeted biologics offer additional therapeutic options, especially for those with concomitant psoriasis (PsO) and axial disease. The proposed biologic sequence derived from clinical trial data and expert opinion incorporates PsA disease severity as well as concomitant PsO and axial disease in the setting of biologic nonresponse. This approach aims to guide clinicians in selecting the most effective therapy while conserving future treatment options. However, gaps remain in understanding the sequential use of IL-17 and IL-23 inhibitors, particularly in axial disease, emphasizing the need for further research and real-world clinical data.

Indexed as

BiologicsBiologics and psoriasisBiologics and psoriatic arthritisNonresponsePsoriasis

Identifiers

PMID40679752
PMCPMC12354416

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.